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Abstract
Background: Human Parainfluenza Virus (hPIV) causes severe respiratory illness in infants and adults. Our study
describes the association of hPIV1–4 with bronchiolitis, croup, and pneumonia using retrospective laboratory,
administrative and public health data. Due to issues including the historic lack of hPIV4 in some commercial
respiratory virus panels, the description of the impact of hPIV4 on croup, bronchiolitis, and pneumonia at population
levels has often been limited. This study will use routine clinical laboratory data, and administrative data to provide a
preliminary description of the impact of hPIV4 on these diseases in our population.
Methods: A three year cohort of patients positive for hPIV was linked with data from physician visits and hospital
admissions to define cases and hospitalization status. International Classification of Disease (ICD-9) codes were used to
determine if cases had croup, bronchiolitis, and pneumonia. We also looked at differences in hospitalization status, age
and gender among hPIV1–4. All statistical analysis was done using SPSS (Version 19.0.0, IBM Corp© 2010) and
Graphpad Prism V6 (GraphPad Software, Inc., 2012).
Results: Only hPIV1 and hPIV4 specimens had positivity rates greater than 5 % of all specimens sent for respiratory
virus panel testing. hPIV1 exhibited a biennial pattern while the pattern for hPIV3 was less interpretable due to lower
positivity rates. Circulation patterns for hPIV2 and hPIV4 were not assessed due to the low positivity rates of theses
specimens. From 2010 to 2013, there were 2300 hPIV cases with hPIV3 (46 %) being the most common, followed by
hPIV1 (27 %), hPIV4 (16 %) and hPIV2 (11 %). The median age was 2 years for all hPIV types. Males were slightly greater
than females for hPIV1 and hPIV2, with an equal distribution for hPIV3 and slightly more females than males for hPIV4.
hPIV1 and hPIV2 had the highest or proportion of croup while hPIV3 and hPIV4 had the highest proportion of
pneumonia. Within hPIV4 cases, distributions of diseases were; pneumonia (21 %, 95 % CI 17.1–25.7), bronchiolitis
(18 %, 95 % CI 14.3–22.5), croup (2 %, 95 % CI 0.8–3.9), mixed illness of any of pneumonia, bronchiolitis or croup
(4 %, 95 % CI 2.5–7.0) or other respiratory diseases (54 %, 95 % CI 49.1–59.6).
Conclusions: We used laboratory and administrative data to undertake a descriptive analysis of the association of
hPIV1–4 with croup, bronchiolitis and pneumonia. hPIV4 appears to be more associated more with bronchiolitis
and pneumonia and less with croup in our population.
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Background
Respiratory illness due to viral infections represents a
significant burden on the healthcare system and our
jurisdiction is highly impacted by respiratory viruses
from later summer until early spring [1]. Human
Parainfluenzavirus (hPIV) is a single stranded RNA
virus belonging to Paramyxoviridae family, and all
four types are a significant cause of respiratory illness,
in infants and elderly [2]. hPIVs cause upper respira-
tory tract illness (URTI) such as colds, otitis media,
and pharyngitis or lower respiratory tract illness
(LRTI) such as croup, bronchiolitis and pneumonia
[3–5]. In adults, the infection tends to stay in the
upper respiratory tract; however morbidity in children
under the age of five can be severe, with hospitaliza-
tions due to pneumonia, croup, and bronchiolitis [2].
The four types of parainfluenza differ in their clinical
outcomes. hPIV1 and 2 have been associated with
croup in children (acute laryngotracheobronchitis) [6],
while hPIV3 has been described in bronchiolitis and
pneumonia [7].
Although hPIV4 has been described in studies using
laboratory developed tests, it has not often been in-
cluded in some commercial respiratory viral panels and
so large scale systematic surveillance may not have in-
cluded hPIV4 due to regulatory issues [8]. We note that
there is already some work suggesting an association of
hPIV4 infections with pneumonia [9] and some specula-
tion that hPIV4 infections might resemble hPIV3 infec-
tions [10, 11]. However, studies on the impact of HPIV4
on specific diseases have been limited to locations that
able to overcome this limitation and integrate testing
into diagnostic algorithms and that studies may not have
focused on whole populations. In contrast, our labora-
tory provides centralized testing for our Province
(Population 4.1 Million) and was one of the early
adopters of a diagnostic that could differentiate hPIV4
from hPHIV1-3 on a population level over a period of
several years [10, 12, 13]. Due to a number of historical
factors, we also undertake extremely high levels of
respiratory virus testing a year with this technology
(approximately 30,000 specimens a year), for a variety of
patient populations which allows us extensive coverage
of a large population from a variety of settings. Similarly,
our publically funded health care system allows us to
link billing codes indicating suspect diagnosis to patient
laboratory information.
We also wanted to determine whether hPIV4 infec-
tions exhibited similar patterns of prevalence to other
hPIV types. Variability of temporal and seasonal patterns
of prevalence (annual, biannual, biennial) for hPIV types
have been described in the literature but the data for
hPIV4 has been relatively less described [14]. hPIV4 in-
fections in other populations have been described as
occurring in a year round distribution, with biennial
peaks in odd-numbered years and a spectrum of disease
[10]. In contrast prevalence patterns for the other hPIV
types 1–3 may vary. Some studies in the United States
have also shown that hPIV1 occurs in the fall of odd
numbered years and hPIV2 occurs in even-numbered
years [15]. While hPIV3 is observed year round, it tends
to peak primarily in the spring and early summer [16] or
might have a biannual pattern of prevalence [10]. HPIV2
has shown to have varied seasonal distribution, often oc-
curring in multiple seasons and characterization of sea-
sonality for HPIV2 is further confounded by the low
prevalence of this virus [17, 18].
Therefore, the purpose of the study is to use routine
clinical laboratory data, and administrative data collected
by public health to provide a preliminary description of
the impact of hPIV4 on croup, bronchiolitis and pneu-
monia in our population. We intended to do this by
comparing the distribution of ICD9 codes associated
with these diseases between different hPIV types. We
also wanted to provide a better understanding of the cir-
culation patterns of PIV4 over time in our province.
Methods
Alberta is the fourth largest province in Canada with a
population of 4.1 million [19]. Alberta has universal
health care; as such, all inpatient and outpatient visits to
physicians, emergency departments, and hospitals for all
Alberta residents are billed to the Alberta Ministry of
Health. All Alberta residents are issued a unique Public
Health Number (PHN) at birth or upon moving to the
province. Physicians are required to include this identi-
fier and the diagnosis of the patient when billing for
inpatient or outpatient services.
The Provincial Laboratory for Public Health (ProvLab)
is a major diagnostic lab in the province of Alberta. All
inpatient and outpatient respiratory samples throughout
the province are labeled with the patient’s PHN and sent
to ProvLab for laboratory testing and the resulting test
results are exported and stored in a database. For the
time period in this analysis, the determination to order
respiratory virus testing was left to the discretion of the
ordering physician and there were not recommendations
provided on when a respiratory virus panel should be or-
dered. In combining the ProvLab and Ministry of Health
data sources, it is possible to determine the organism an
Alberta resident was infected with, whether they were
seen as an inpatient or an outpatient, and whether they
were hospitalized. The study utilized this capability to
describe the epidemiology of hPIV1–4 in the population
of Alberta.
During the study period, all respiratory specimens were
routinely tested for influenza A and influenza B using a
real-time reverse transcriptase-real time polymerase chain
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reaction (RT-PCR) assay as previously described [1]; if
found negative, they were tested by the XTAG®
Respiratory Viral Panel (RVP, Luminex, Austin, TX,
USA) for several other common respiratory pathogens
including, hPIV1–4 [20]. Clinical respiratory samples
from Alberta residents received at the ProvLab be-
tween November 1, 2010 and December 31, 2013 that
tested positive for hPIV1–4 were eligible for the study.
Specimen positivity rates were calculated by determining
the number of positive hPIV1–4 specimens detected
versus the number of specimens that were tested by the
RVP panel.
As patients could have multiple samples sent for test-
ing, only the first positive sample for an individual
within a 365 day period for a specific type of hPIV was
allowed in the study. Subsequent positive tests were ex-
cluded within the 365 day period, unless they were posi-
tive for a different type of hPIV, at which time they were
considered a different case of disease. This period of
time was chosen as we wanted to ensure that the values
we presented were conservative estimates of the number
of cases diagnosed during the study period. Cases that
were co-infected with more than one type of hPIV or co-
infected with another virus (such as rhino-enterovirus or
respiratory syncytial virus [RSV].) were also excluded from
the analysis to prevent the confounding effect of other vi-
ruses that may also be associated with croup, bronchiolitis
and pneumonia [21].
Positive cases of hPIV were deterministically linked
to administrative data using the PHN. The physician
claims data in the Supplemental Enhanced Service
Event (SESE) database was used to provide the World
Health Organization (WHO) International Classification
of Diseases 9 Codes (ICD 9) [22] associated with the phys-
ician visit and associated hIPV laboratory result. Three
ICD 9 codes were extracted from the SESE database along
with patient demographic characteristics. There were
often multiple ICD9 codes, for the non-croup, non-
bronchiolitis, and non-pneumonia case group. For this
group frequencies of other disease codes included;
“infectious diseases” (001–139), “ill defined condition”
(780–799), acute respiratory infections (460–466);
other diseases of the respiratory system (467–519),
diseases of the ear and mastoid process (380–389),
other diseases of the central nervous system and sense
organs (320–379).
Physician claims data is housed in the Supplemental
Enhanced Service Event System (SESE database); in-
patient hospitalizations, emergency department visits,
and outpatient clinic data is housed in the Morbidity
and Ambulatory Care Abstracting Reporting (MACAR)
system, which feeds into the Canadian Institute for
Health Information’s (CIHI) Discharge Abstract Database
(DAD) and National Ambulatory Care Reporting System
(NACRS). [23]. The hospitalization data provided infor-
mation on whether the case was hospitalized and the dur-
ation of hospitalization.
These databases were utilized to determine demo-
graphic information, and to determine if a hPIV case
was diagnosed with croup, pneumonia, or bronchiolitis
within 14 days of their positive parainfluenza specimen.
Table 1 lists the ICD-9 codes used to define each diag-
nosis. “Single diagnosis” was defined as hPIV cases that
had one event of croup, bronchiolitis or pneumonia.
“Mixed diagnoses” were defined as hPIV cases diagnosed
with two or more events (i.e. croup and pneumonia).
Descriptive statistics regarding demographic character-
istics and clinical diagnosis of hPIV1–4 cases were
performed. We also described the distribution of hPIV
cases over time. Proportions, means, medians were per-
formed using SPSS (Version 19.0.0, IBM Corp© 2010).
Graphpad Prism (V6, (GraphPad Software, Inc., 2012)
was used to obtain 95 % confidence interval (CI) of
proportions. Fisher’s exact and Chi- square tests were
utilized to test for statistical significance.
Results
Identification of positive hPIV cases was carried out as
follows. A total of 55,112 specimens were tested for
hPIV and included in the study. 63.5 % (51,888/81,587)
specimens tested negative for hPIV, leaving 3224 positive
specimens. Negatives were not included in Table 2 be-
cause the point of this analysis was to compare the dis-
tribution of ICD9 codes for croup, bronchiolitis, and
pneumonia with specific hPIV types. Of those 3224
specimens, 316 were considered duplicate (i.e. based on
case definition), leaving 2908 unique cases of hPIV.
Twenty five cases were unable to be linked to the SESE
and MACAR databases due to invalid PHN’s or other
personal identifiers and were therefore excluded from
study at this point. We were left with 2883 cases of hPIV
that were linked to SESE and MACAR. Furthermore we
excluded 19 cases that had mixed hPIVs, and 564 cases
that were co-infected with other respiratory viruses leav-
ing a total of 2300 unique hPIV cases over a three year
period.
As in Table 2, hPIV4 was the third most common
hPIV type making up 16 % of all hPIV cases. Out of all
the cases, hPIV3 was the most common (46 %) type
Table 1 Description of ICD-9 codes used to diagnose hPIV
laboratory tested cases with public health administrative
databases
Diagnosis ICD-9 diagnostic codes
Croup 464, 464.1, 464.4, 464.3, 464.4
Bronchiolitis 466, 466.0, 466.1
Pneumonia 480–486 (inclusive)
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followed by hPIV1 (27 %). hPIV2 was the least common
of all the hPIV cases (11 %). The median age was 2 years
(range: 0.01–103 years) for all hPIV types. Males were
slightly greater than females for hPIV1 and hPIV2, with
an equal distribution for hPIV3 and slightly more fe-
males than males for hPIV4. Greater than 50 % of cases
were non-hospitalized (Table 2). Over 50 % of cases were
associated with ICD-9 codes related to other respiratory
diseases that were not croup, bronchiolitis and pneumo-
nia. As shown in Table 3, 95 % confidence intervals of
the hPIV types for hospitalized cases all overlapped
which indicated to use that were no able to comfortably
infer a dominance of any one type in this population.
The same inability to infer a dominant type of hPIV was
also found with the non-hospitalized group. hPIV1 and
hPIV2 had the highest percentages of croup while hPIV3
and hPIV4 had the highest percentages of pneumonia.
Within hPIV4 cases, distributions of diseases were;
pneumonia (21 %, 95 % CI 17.1–25.7), bronchiolitis
(18 %, 95 % CI 14.3–22.5), croup (2 %, 95 % CI 0.8–3.9),
mixed illness of any of pneumonia, bronchiolitis or
croup (4 %, 95 % CI 2.5–7.0) or other respiratory dis-
eases (54 %, 95 % CI 49.1–59.6).
The association of PIV1-4 was also assessed for other
disease codes for the non-croup, non-bronchiolitis, and
non-pneumonia cases (n = 1267). As there were multiple
ICD9 codes, for each non-case in this group, frequencies
of other disease codes were described. Many of these
were relatively non-specific. Frequencies for “infectious
diseases” (001–139) for each PIV type were; PIV1
[52/313, 16.61 %), PIV2 (30/132, 22.72 %), PIV3 (78/
624, 12.50 %), and PIV4 (23/198. 11.62 %). Frequen-
cies for “ill defined condition” (780–799) for PIV
types were; PIV1 (137/313, 43.77 %), PIV2 (50/132,
37.88 %), PIV3 (252/624, 40.38 %), and PIV4 (87/198,
43.94 %). Frequencies for acute respiratory infections
(460–466) for PIV types were; PIV1 (114/313,
36.42 %), PIV2 (38/132, 28.79 %), PIV3 (162/624,
25.96 %), and PIV4 (54/198, 27.27 %). Frequencies for
other diseases of the respiratory system (467–519) for
PIV types were; PIV1 (58/313, 18.53 %), PIV2 (26/
132, 19.70 %), PIV3 (159/625, 25.44 %), an PIV4 (40/
198, 20.20 %). Frequencies of, diseases of the ear and
mastoid process (380–389) for each PIV type were;
PIV1 (13/313, 4.15 %), PIV2 (4/132, 3.03 %), PIV3
(27/624, 4.32 %), and PIV4 (7/198, 3.53 %). Frequen-
cies for other diseases of the central nervous system
and sense organs (320–379) for each PIV type were;
PIV1 (17/313, 5.43 %), PIV2 (5/132, 3.79 %), PIV3
(56/624, 8.97 %), and PIV4 (14/198, 7.07 %). No sig-
nificant difference was seen between PIV type and
diseases of the “ear and mastoid” (Chi-square, p = 0.89)
nor for other diseases of the “nervous system and sense
organs (Chi-square, p = 0.0724).
As in Fig. 1, only hPIV1 and hPIV3 specimens had
peak positivity rates greater than 5 %. The peak patterns
for hPIV1 were more defined and there appeared to be
two winter peaks each separated by a one year period
with no hPIV1 peak in what can be described as a
biennial pattern (Fig. 1a). The peak patterns for hPIV3
(Fig. 1c) were less defined with one major peak in the
winter period of 2010–2011, which occurred out of cycle
with the hPIV1 peaks. Latter peaks for hPIV3 were less
easy to interpret due to lower positivity rates that hov-
ered around the five percent positivity level. Temporal
peak patterns for hPIV2 (Fig. 1b) and hPIV4 (Fig. 1d)
were not assessed as these did not peak above 5 %
positivity.
Table 2 Descriptive analysis of all combined hPIV cases
laboratory and public health linked cases 2010–2013






Median age years (range) 2 (0.01–103)
Age
0–1 years 1049 (46)
2–4 years 386 (17)
5–8 years 154 (7)
9–11 years 32 (1.4)
12–17 years 52 (2.3)
18–64 years 367 (16)













Mixed cases that have Croup Bronchiolitis and Pneumonia 103 (5)
Other clinical or respiratory disease 1267a (55)
51,888 negative specimens were excluded from analysis as the goal of this
study was to compare the distribution of ICD9 codes for croup, bronchiolitis
and pneumonia for hPIV1–4
a These cases had a respiratory disease ICD-9 code that was not specific
for croup, bronchiolitis or pneumonia. Out of 1267 cases, 835 (63 %)
were non-hospitalized
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Discussion
This study uses administrative and hospitalization codes
to link clinical laboratory data from hPIV1–4 cases to a
clinical diagnosis (e.g. croup, bronchiolitis, pneumonia)
and to determine patient setting (hospital or non-
hospitalized). ICD-9 codes have been shown to be valid
markers of a true history of pneumonia and can be used
to successfully identify infection-related conditions in
epidemiologic studies [24]. Previous epidemiologic stud-
ies in Canada have used ICD-9 codes to understand pat-
terns of croup. These codes have also been used to
analyze bronchiolitis in epidemiologic studies in a variety
of settings and over time [25–28]. ICD-9 codes have also
been utilized to characterize croup cases on a population
basis in other studies [29, 30]. The use of these data sets
allows for analysis of general trends of illness at popula-
tion levels in a manner that could not be accomplished
with later more detailed chart reviews and surveys of
electronic health records. We have also previously used
hospitalization diagnosis codes in our jurisdiction to
understand patient location trends on a population level
[20]. However, we hope that linking multiple databases
will lead to additional studies that can provide a greater
understanding of the role that that these hPIV types play
in acute respiratory infections. Using administrative and
clinical data we were able to study a largely pediatric
patient population with nearly three quarters of all
hPIV-positive patients age 12 or younger, and 42 % of
hPIV cases as being hospitalized.
This work sheds light on some basic characteristics of
hPIV4 infection at a larger population level. Of all the
hPIV types, the clinical and epidemiologic presentation
of hPIV4 on a large population level have been the least
studied [10], although hPIV4 has been described as a
cause of acute influenza-like-illness (ILI) in both adults
and children in a variety of settings [13, 31–34]. This in-
creasing body of work contrasts to earlier studies which
identified hPIV4 as being associated with mild disease
[35] or predominantly upper respiratory tract infections
[36]. Instead, our descriptive analysis aligns more with
recent studies describing hPIV4 in acute lower re-
spiratory tract infections in pediatric patients [36, 37],
as an etiologic agent in hospitalized cases of commu-
nity acquired pneumonia [38], or being associated
with bronchiolitis. This difference in disease patterns
may be due to the broader sampling from our study
(e.g. the whole jurisdiction) including acute care and
tertiary care facilities instead of community settings.
Thus, we may be identifying a physician bias towards
testing patients who are more ill and we maybe cases
who have a greater severity of illness and are more
likely to be evaluated.
Table 3 Descriptive analysis of hPIV laboratory and public health linked cases depending on type
hPIV1 (N = 617)
n (%)
95 % CI hPIV2 (N = 252)
n (%)
95 % CI hPIV3 (N = 1067)
n (%)
95 % CI hPIV4 (N = 364)
n (%)
95 % CI
Hospitalizeda 259 (42) 38.0–45.9 107 (42) 36.2–48.8 436 (41) 37.9–43.9 166 (46) 40.4–50.8
Non-Hospitalized 358 (58) 54.0–61.9 145 (58) 51.1–63.7 631 (59) 56.1–62.0 198 (54) 49.1–59.5
<2 yearsb 285 (46) 42.2–50.2 101 (40) 34.0–46.4 505 (47) 44.3–50.4 158 (44) 38.1–48.5
2–4 years 141 (23) 19.6–26.4 40 (16) 11.6–21.0 146 (14) 11.7–15.9 59 (16) 12.6–20.5
5–8 years 62 (10) 7.8–12.7 36 (14) 10.2–19.2 28 (3) 1.8–3.8 28 (8) 5.2–11.0
9–11 years 7 (1) 0.5–2.3 12 (5) 2.5–8.2 9 (0.8) 0.4–1.4 4 (1.1) 0.3–2.8
12–17 years 10 (2) 0.8–3.0 6 (2) 0.9–5.1 24 (2.2) 1.4–3.3 12 (3.3) 1.7–5.7
18–64 years 78 (13) 10.1–15.5 33 (13) 9.2–17.9 183 (17) 14.9–19.5 73 (20) 16.1–24.6
65 + years 34 (6) 3.8–7.6 23 (9) 5.9–13.4 172 (16) 14.0–18.5 30 (8.2) 5.6–11.6
Unk 0 (0) 0.0–0.6 1 (0.4) 0.0–2.2 0 (0) 0.0–0.3 0 (0) 0.0–1.0
Malec 343 (56) 51.6–59.6 138 (55) 48.4–61.0 538 (50) 47.4–53.5 177 (49) 43.4–53.9
Female 270 (44) 39.8–47.8 113 (45) 38.6–51.2 523 (49) 46.0–52.1 184 (51) 45.3–55.8
Unknown 4 (0.65) 0.2–1.7 1 (0.39) 0.0–2.2 6 (0.6) 0.2–1.2 3 (0.8) 0.2–2.4
Croupd 133 (22) 18.4–25.0 47 (19) 14.0–24.0 61 (6) 4.4–7.3 7 (2) 0.8–3.9
Pneumoniae 74 (12) 9.5–14.8 33 (13) 9.2–17.9 193 (18) 15.8–20.5 77 (21) 17.1–25.7
Bronchiolitisf 64 (11) 8.1–13.1 27 (11) 7.2–15.2 148 (14) 11.9–16.1 66 (18) 14.3–22.5
Mixedg 33 (5) 7.4–37.0 13 (5) 8.7–28.0 41 (4) 2.8–5.2 16 (4) 2.5–7.0
Other respiratory disease 313 (50) 46.7–54.7 132 (52) 46.0–58.7 624 (58) 55.5–61.5 198 (54) 49.1–59.6
Mixed means case has any combination of croup, pneumonia and bronchiolitis
a NS hospitalized vs non-hospitalized for PIV type: P = 0.4717; b NS age for PIV type, P = 0.307; c NS male vs female for PIV type, P = 0.0847
d Chi-square 148.82, df = 3, P < 0.001; e Chi-square 24.13, df = 3, P < 0.001; f Chi-square 13.75, df = 3, P = 0.0033; g Chi-square 10.52, df = 3, P = 0.0146
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One recent study by Frost et al., recently did an excel-
lent job at describing the epidemiology of hPIV4 in hos-
pitalized pediatric patients in Colorado, USA. That study
did not identify any cases of hPIV4 associated with
croup [10]. In contrast, our study found that seven per-
cent of hPIV4 cases were diagnosed with croup. This
may be accounted for by the fact that our study was a
large population-based study over an extended time
period and large geographic area and included both
pediatric and adult, and hospitalized and non-hospitalized
cases.
Although some differences in type-associate disease
profiles are seen in the study against previous work, the
seasonality of hPIV4 was not determined in this study
due to low peak positivity rates of hPIV4 specimens.
Peak hPIV4 activity has been described in the late au-
tumn and early winter [39]. Depending on the study
both hPIV4 and hPIV2, have either annual or biennial
circulation patterns [10]. In contrast a biennial circula-
tion trend was observed for the hPIV1 cases and peak
hPIV3 activity was offset from peak hPIV1 activity by
one year [6, 15, 39–43]. Published and unpublished dif-
ferences in temporal circulation patterns between studies
is not unexpected, as multiple host and environmental
factors impact on the seasonal distributions of these
viruses [44].
There are several limitations to this study. First, the
analysis does not describe the differences between the
two subtypes of hPIV4 [45], and the work excludes co-
infections of hPIV types or co-infections with other re-
spiratory viruses. The study also does not attempt to
understand the deeper clinical histories of patients, in-
cluding factors such as immunocompromised status or
transplant that might be associated with acute respira-
tory infections by specific hPIV types. The lack of a stan-
dardized case definition, reinfection rates, or maximum
shedding periods for parainfluenza impact comparisons
between studies [43, 46–48]. While 1 year may be high,
we felt this was justified as we wanted to ensure that the
values we presented were conservative estimates of the
number of cases diagnosed during the study period, and
that the estimates of hospitalization were not overesti-
mated by the potential inclusion of very ill patients being
tested multiple times for the same illness. However, we
are reassured that only 316 of 3224 specimens were ex-
cluded from the study as duplicates. Finally, this is an
analysis of large sets of administrative and laboratory
data which may yield different conclusions than clinical
studies using chart reviews. Although there is the possi-
bility of errors in diagnostic codes, the authors feel that
the diagnostic codes for emergency department and in-
patient data are valid and reliable due to the rigorous
Fig. 1 Temporal distribution of positive (a) hPIV1 specimens, (b) hPIV2 specimens, (c) hPIV3 specimens and (d) hPIV4 specimens. Only hPIV1 and
hPIV3 specimens had peak rates of positivity greater than 5 % when compared to total numbers of specimens tested by RVP. Rates of hPIV2 and
hPIV4 specimen positivity were consistently below 1.5 and 2.5 % respectively and were not analyzed for seasonal or yearly trends
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training and review that the Canadian Institute for
Health Information (CIHI) imposes [49, 50].
Conclusions
This study suggests that the distribution clinical illnesses
may be different between hPIV4 and hPIV1. While the
proportion of hPIV4 cases diagnosed with croup was
statistically significantly lower than hPIV1 cases, hPIV1
cases were statistically significantly more likely to be di-
agnosed with pneumonia and bronchiolitis. While the
results did not attain statistical significance, a similar
trend was seen with hPIV2. The difference in the distri-
bution of clinical diagnoses in hPIV types suggests that
in the future it may be worthwhile to support hPIV type
specific patient management strategies.
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